Metagenomic Identification of Microbial Signatures Predicting Pancreatic Cancer From a Multinational Study

Naoyoshi Nagata(Tokyo Medical University), Suguru Nishijima(Waseda University), Yasushi Kojima(National Center for Global Health and Medicine), Yuya Hisada(National Center for Global Health and Medicine), Koh Imbe(National Center for Global Health and Medicine), Tohru Miyoshi‐Akiyama(National Center for Global Health and Medicine), Wataru Suda(RIKEN Center for Integrative Medical Sciences), Moto Kimura(National Center for Global Health and Medicine), Ryo Aoki(Ezaki Glico (Japan)), Katsunori Sekine(National Center for Global Health and Medicine), Mitsuru Ohsugi(National Center for Global Health and Medicine), Kuniko Miki(Tokyo Medical University), Tsuyoshi Osawa(The University of Tokyo), Kohjiro Ueki(National Center for Global Health and Medicine), Shinichi Oka(National Center for Global Health and Medicine), Masashi Mizokami(National Center for Global Health and Medicine), Ece Kartal(European Molecular Biology Laboratory), Thomas Schmidt(European Molecular Biology Laboratory), Esther Molina‐Montes(Spanish National Cancer Research Centre), Lidia Estudillo(Spanish National Cancer Research Centre), Núria Malats(Spanish National Cancer Research Centre), Jonel Trebicka(Goethe University Frankfurt), Stephan Kersting(Universitätsmedizin Greifswald), Melanie Langheinrich(Universitätsmedizin Greifswald), Peer Bork(University of Würzburg), Naomi Uemura(Tokyo Medical University), Takao Itoi(Tokyo Medical University), Takashi Kawai(Tokyo Medical University)
Gastroenterology
April 8, 2022
Cited by 212Open Access
Full Text

Abstract

Background & AimsTo identify gut and oral metagenomic signatures that accurately predict pancreatic ductal carcinoma (PDAC) and to validate these signatures in independent cohorts.MethodsWe conducted a multinational study and performed shotgun metagenomic analysis of fecal and salivary samples collected from patients with treatment-naïve PDAC and non-PDAC controls in Japan, Spain, and Germany. Taxonomic and functional profiles of the microbiomes were characterized, and metagenomic classifiers to predict PDAC were constructed and validated in external datasets.ResultsComparative metagenomics revealed dysbiosis of both the gut and oral microbiomes and identified 30 gut and 18 oral species significantly associated with PDAC in the Japanese cohort. These microbial signatures achieved high area under the curve values of 0.78 to 0.82. The prediction model trained on the Japanese gut microbiome also had high predictive ability in Spanish and German cohorts, with respective area under the curve values of 0.74 and 0.83, validating its high confidence and versatility for PDAC prediction. Significant enrichments of Streptococcus and Veillonella spp and a depletion of Faecalibacterium prausnitzii were common gut signatures for PDAC in all the 3 cohorts. Prospective follow-up data revealed that patients with certain gut and oral microbial species were at higher risk of PDAC-related mortality. Finally, 58 bacteriophages that could infect microbial species consistently enriched in patients with PDAC across the 3 countries were identified.ConclusionsMetagenomics targeting the gut and oral microbiomes can provide a powerful source of biomarkers for identifying individuals with PDAC and their prognoses. The identification of shared gut microbial signatures for PDAC in Asian and European cohorts indicates the presence of robust and global gut microbial biomarkers. To identify gut and oral metagenomic signatures that accurately predict pancreatic ductal carcinoma (PDAC) and to validate these signatures in independent cohorts. We conducted a multinational study and performed shotgun metagenomic analysis of fecal and salivary samples collected from patients with treatment-naïve PDAC and non-PDAC controls in Japan, Spain, and Germany. Taxonomic and functional profiles of the microbiomes were characterized, and metagenomic classifiers to predict PDAC were constructed and validated in external datasets. Comparative metagenomics revealed dysbiosis of both the gut and oral microbiomes and identified 30 gut and 18 oral species significantly associated with PDAC in the Japanese cohort. These microbial signatures achieved high area under the curve values of 0.78 to 0.82. The prediction model trained on the Japanese gut microbiome also had high predictive ability in Spanish and German cohorts, with respective area under the curve values of 0.74 and 0.83, validating its high confidence and versatility for PDAC prediction. Significant enrichments of Streptococcus and Veillonella spp and a depletion of Faecalibacterium prausnitzii were common gut signatures for PDAC in all the 3 cohorts. Prospective follow-up data revealed that patients with certain gut and oral microbial species were at higher risk of PDAC-related mortality. Finally, 58 bacteriophages that could infect microbial species consistently enriched in patients with PDAC across the 3 countries were identified. Metagenomics targeting the gut and oral microbiomes can provide a powerful source of biomarkers for identifying individuals with PDAC and their prognoses. The identification of shared gut microbial signatures for PDAC in Asian and European cohorts indicates the presence of robust and global gut microbial biomarkers.


Related Papers